<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "https://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="1.2" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJMABHR</journal-id>
<journal-title-group><journal-title>International Journal of Medical and All Body Health Research</journal-title><abbrev-journal-title>IJMABHR</abbrev-journal-title></journal-title-group>
<issn pub-type="epub">2582-8940</issn>
<publisher><publisher-name>Anfo Publication House</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">32</article-id>
<title-group><article-title>Treatment and vaccination of Covid-19</article-title></title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Akram</surname><given-names>Muhammad</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author"><name><surname>Riaz</surname><given-names>Tehreem</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author"><name><surname>Ishtiaq</surname><given-names>Isha</given-names></name><xref ref-type="aff" rid="aff2"/></contrib>
<contrib contrib-type="author"><name><surname>Riaz</surname><given-names>Husnain Karim</given-names></name><xref ref-type="aff" rid="aff3"/></contrib>
<contrib contrib-type="author"><name><surname>Shahzadi</surname><given-names>Sana</given-names></name><xref ref-type="aff" rid="aff2"/></contrib>
<contrib contrib-type="author"><name><surname>Talat</surname><given-names>Marriyam</given-names></name><xref ref-type="aff" rid="aff2"/></contrib>
<contrib contrib-type="author"><name><surname>Irfan</surname><given-names>Saba</given-names></name><xref ref-type="aff" rid="aff3"/></contrib>
<contrib contrib-type="author"><name><surname>Farooq</surname><given-names>Wasfa</given-names></name><xref ref-type="aff" rid="aff3"/></contrib>
<contrib contrib-type="author"><name><surname>Khan</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="aff2"/></contrib>
<aff id="aff1"><label>1</label>Department of Eastern Medicine, Government College University Faisalabad Pakistan</aff>
<aff id="aff2"><label>2</label>Department of Biotechnology, University of Sialkot, Pakistan</aff>
<aff id="aff3"><label>3</label>Department of Microbiology, University of Central Punjab, Pakistan</aff>
</contrib-group>
<pub-date publication-format="electronic" date-type="pub"><year>2020</year></pub-date>
<volume>1</volume>
<issue>2</issue>
<fpage>01</fpage>
<lpage>07</lpage>
<history>
<date date-type="received"><day>25</day><month>02</month><year>2020</year></date>
<date date-type="accepted"><day>10</day><month>03</month><year>2020</year></date>
</history>
<permissions><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-sa/4.0/?utm"><license-p>CC BY-NC-SA 4.0</license-p></license></permissions>
<self-uri xlink:href="https://www.allmedicaljournal.com/article/32/treatment-and-vaccination-of-covid-19"/>
<self-uri content-type="pdf" xlink:href="https://www.allmedicaljournal.com/article/32/download"/>
<abstract><p>The outbreak of this wide-ranging pandemic has forced the world to identify and produce the therapeutics for the treatment &amp; prevention of it. The Covid-19 is a virulent pneumonia-like disease caused by SARS-COV-2. This pandemic has caused several thousands of deaths. For a few months this pandemic has set pressure on laborites to diagnose this novel virus properly and on the pharmacists, researchers, doctors, scientists, and pharmaceutical companies to develop proper medicine and vaccination against this virus. Proper diagnosis and treatment are essential to treat patients suffering from covid-19. Despite extraordinary advancements in the medical field, presently, there is no effective treatment for this global pandemic. However, fast and rapid research on the epidemiology of SARS-COv-2 is helping in unveiling the potential therapeutic against covid-19.clinical trials and screening for drug development are going on some drugs. Favipiravir, Remdesivir, &amp; dexamethasone have shown promising potential against covid-19. Interferon, tocilizumab, and convalescent plasma therapy have beneficial effects on viral clearance. Trials are going also going on viral S protein targeting vaccines. This review aims to summarize all current therapeutic advancements and vaccinations in the global medicinal system against covid-19.</p></abstract>
<kwd-group kwd-group-type="author"><kwd>Covid-19</kwd><kwd>clinical features</kwd><kwd>diagnosis</kwd><kwd>treatment of covid-19</kwd><kwd>anti-viral</kwd><kwd>steroids</kwd><kwd>antibiotics</kwd><kwd>vaccination</kwd></kwd-group>
</article-meta>
</front>
<back><ref-list><title>References</title>
<ref id="R1"><label>1</label><mixed-citation>Alhazzani W, Møller M, Arabi Y, Loeb M, Gong M, Fan E, Du B. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive care medicine, 2020, 1-34.</mixed-citation></ref>
<ref id="R2"><label>2</label><mixed-citation>Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? The Journal of Immunology. 2009; 183(11):6883-6892.</mixed-citation></ref>
<ref id="R3"><label>3</label><mixed-citation>Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D, De Clercq E. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. Journal of medicinal chemistry. 2006; 49(9):2845-2849.</mixed-citation></ref>
<ref id="R4"><label>4</label><mixed-citation>Bonow R, Fonarow G, O’Gara P, Yancy C. Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality JAMA Cardiol. Published online March, 2020, 27.</mixed-citation></ref>
<ref id="R5"><label>5</label><mixed-citation>Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proceedings of the National Academy of Sciences. 2004; 101(26):9804-9809.</mixed-citation></ref>
<ref id="R6"><label>6</label><mixed-citation>Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020; 105932:(10.1016).</mixed-citation></ref>
<ref id="R7"><label>7</label><mixed-citation>Commission, N. H. (2020). Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7). Chin Med J (Engl), 133(9), 1087-1095.</mixed-citation></ref>
<ref id="R8"><label>8</label><mixed-citation>Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., &amp; Einav, S. (2020). A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of critical care.</mixed-citation></ref>
<ref id="R9"><label>9</label><mixed-citation>CS, S., &amp; Madathilkovilakathu, H. (2020). Drug repurposing for COVID-19 from FDA approved and experiment stage drugs by in silico methods with SARS CoV-2 spike protein.</mixed-citation></ref>
<ref id="R10"><label>10</label><mixed-citation>Delang, L., Abdelnabi, R., &amp; Neyts, J. (2018). Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral research, 153, 85-94.</mixed-citation></ref>
<ref id="R11"><label>11</label><mixed-citation>Gautret, P., Lagier, J.-C., Parola, P., Meddeb, L., Mailhe, M., Doudier, B., . . . Dupont, H. T. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents, 105949.</mixed-citation></ref>
<ref id="R12"><label>12</label><mixed-citation>Hui, D. S., Azhar, E. I., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., . . . Drosten, C. (2020). The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases, 91, 264-266.</mixed-citation></ref>
<ref id="R13"><label>13</label><mixed-citation>Khalid, N., Chen, Y., Case, B. C., Shlofmitz, E., Wermers, J. P., Rogers, T., . . . Waksman, R. (2020). COVID-19 (SARS-Cov-2) and the heart–An ominous association. Cardiovascular Revascularization Medicine.</mixed-citation></ref>
<ref id="R14"><label>14</label><mixed-citation>Leng, Z., Zhu, R., Hou, W., Feng, Y., Yang, Y., Han, Q., . . . Wang, S. (2020). Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging and disease, 11(2), 216.</mixed-citation></ref>
<ref id="R15"><label>15</label><mixed-citation>Liu, Y., Li, J., &amp; Feng, Y. (2020). Critical care response to a hospital outbreak of the 2019-nCoV infection in Shenzhen, China: BioMed Central.</mixed-citation></ref>
<ref id="R16"><label>16</label><mixed-citation>Matzneller, P., Krasniqi, S., Kinzig, M., Sörgel, F., Hüttner, S., Lackner, E., . . . Zeitlinger, M. (2013). Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrobial agents and chemotherapy, 57(4), 1736-1742.</mixed-citation></ref>
<ref id="R17"><label>17</label><mixed-citation>Organization, W. H. (2014). Use of convalescent whole International Journal of Medical and all body Health Research http://www.allmedicaljournal.com 7 blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks: interim guidance for national health authorities and blood transfusion services: World Health Organization.</mixed-citation></ref>
<ref id="R18"><label>18</label><mixed-citation>Park, S.-Y., Kim, J.-H., Kim, H.-J., Seo, B., Kwon, O. Y., Chang, H. S., . . . Park, C.-S. (2018). High prevalence of asthma in elderly women: findings from a Korean national health database and adult asthma cohort. Allergy, asthma &amp; immunology research, 10(4), 387-396.</mixed-citation></ref>
<ref id="R19"><label>19</label><mixed-citation>Ratia, K., Pegan, S., Takayama, J., Sleeman, K., Coughlin, M., Baliji, S., . . . Johnson, M. E. (2008). A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proceedings of the National Academy of Sciences, 105(42), 16119-16124.</mixed-citation></ref>
<ref id="R20"><label>20</label><mixed-citation>Rauch, S., Jasny, E., Schmidt, K. E., &amp; Petsch, B. (2018). New vaccine technologies to combat outbreak situations. Frontiers in immunology, 9, 1963.</mixed-citation></ref>
<ref id="R21"><label>21</label><mixed-citation>Roden, D. M., Harrington, R. A., Poppas, A., &amp; Russo, A. M. (2020). Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment. Circulation.</mixed-citation></ref>
<ref id="R22"><label>22</label><mixed-citation>Savarino, A., Di Trani, L., Donatelli, I., Cauda, R., &amp; Cassone, A. (2006). New insights into the antiviral effects of chloroquine. The Lancet infectious diseases, 6(2), 67-69.</mixed-citation></ref>
<ref id="R23"><label>23</label><mixed-citation>Scagnolari, C., Vicenzi, E., Bellomi, F., Stillitano, M. G., Pinna, D., Poli, G., . . . Antonelli, G. (2004). Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther, 9(6), 1003-1011.</mixed-citation></ref>
<ref id="R24"><label>24</label><mixed-citation>Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., . . . Clarke, M. O. (2020). Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. nature COMMUNICATIONS, 11(1), 1-14.</mixed-citation></ref>
<ref id="R25"><label>25</label><mixed-citation>Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., . . . Xing, L. (2020). Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA, 323(16), 1582-1589.</mixed-citation></ref>
<ref id="R26"><label>26</label><mixed-citation>Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., . . . Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research, 30(3), 269-271.</mixed-citation></ref>
<ref id="R27"><label>27</label><mixed-citation>Xing, Z., Afkhami, S., Bavananthasivam, J., Fritz, D. K., D&apos;Agostino, M. R., Vaseghi‐Shanjani, M., . . . Jeyanathan, M. (2020). Innate immune memory of tissue‐resident macrophages and trained innate immunity: Re‐vamping vaccine concept and strategies. Journal of leukocyte biology.</mixed-citation></ref>
<ref id="R28"><label>28</label><mixed-citation>Yang, X., Yu, Y., Xu, J., Shu, H., Liu, H., Wu, Y., . . . Yu, T. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine.</mixed-citation></ref>
<ref id="R29"><label>29</label><mixed-citation>Yao, Y., Jeyanathan, M., Haddadi, S., Barra, N. G., Vaseghi-Shanjani, M., Damjanovic, D., . . . Dvorkin-Gheva, A. (2018). Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity. Cell, 175(6), 1634-1650. e1617.</mixed-citation></ref>
<ref id="R30"><label>30</label><mixed-citation>Saeed, U., Uppal, S. R., Piracha, Z. Z., Khan, A. A., Rasheed, A., Waheed, A., ... &amp; Uppal, R. (2021). Evaluation of SARS-CoV-2 spike antibody levels among Sputnik V first dose vaccinated people in Pakistan: formulation of national anti-COVID-19 mass vaccination strategy.</mixed-citation></ref>
<ref id="R31"><label>31</label><mixed-citation>Khurana, A., Allawadhi, P., Khurana, I., Allwadhi, S., Weiskirchen, R., Banothu, A. K., ... &amp; Bharani, K. K. (2021). Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Nano Today, 38, 101142.</mixed-citation></ref>
</ref-list></back>
</article>